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ABSTRACT 
Risperidone is an atypical antipsychotic with broad spectrum of antipsychotic activity and 
lower potential for extrapyramidal side effects at therapeutic doses. This case report illustrates the 
development of tardive dyskinesia with therapeutic dose of risperidone in a paranoid schizophrenic 
patient who was not on any antipsychotic medication previously. 
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Risperidone, a recently approved 
antipsychotic drug, is a benzisoxizole derivative 
that displays potent central antagonism of 
serotonin (especially 5HT2) as well as dopamine 
(D,) receptors Because of its broad spectrum 
of pharmacologic properties, particularly its 5HT2 
antagonism, risperidone has been regarded as 
an atypical antipsychotic that shares with 
clozapine the potential for superior antipsychotic 
efficacy and reduced capacity for causing 
extrapyramidal side effects including tardive 
dyskinesia (Marder and Meibach,1994; Jeste et 
al., 1999). There are reports that risperidone even 
supresses abnormal movements in patients with 
tardive dyskinesia (Chouinard,1995). However 
there are isolated cases of tardive dyskinesia 
reported with risperidone treatment (Addington 
et al ,1995; Woener et al.,1996; Gwinn and 
Caviness,1997, Silberbauer,1989, Saran,1998). 
A recent case report (Carroll et al., 1999) 
described an adolescent taking risperidone, 6 
mg/day who had mild hand-dangling movements 
and tongue protrusion; these subsided with 
discontinuation of risperidone. Evidence from 
over 1100 patients, 503 of whom had taken 
risperidone for at least 1 year, suggest that the 
annual incidence of tardive dyskinesia in patients 
taking risperidone (7.6-9.4 mg/day) is 0.3%, 
compared to an annual incidence of 5-10% in 
patients taking conventional neuroleptics 
(Gutierrez-Esteinou & Grebb,1997). In view of 
the interesting nature of the subject, we describe 
a patient who develop extrapyramidal side effects 
that were followed by dyskinetic movements in 
association with risperidone treatment. 
Mr. G, was a 48 year old, married, Christian 
male, with a 10-year history of persecutory 
delusions, referential delusion, delusion of 
infidelity and grandiose delusion of ability. 
Because of these problems, he had taken 
voluntary retirement from military service 5 years 
ago, but was not willing to consult a psychiatrist. 
Two years earlier, he had been forcefully admitted 
to our hospital with exacerbation of paranoid 
schizophrenia. There was no significant past or 
family history of psychiatric disturbances. Physical 
examination and routine investigations were 
within normal limits. He was a chain smoker and 
used to consume alcohol occasionally. During in-
patient stay he had received trifluperazine 
(maximum dose, 20 mg/day) and trihexiphenidyl 
(4 mg/day). After discharge he was irregular on 
medication and relapsed. At this time, he was 
prescribed liquid risperidone, the dose of which 
was gradually increased to a maximum of 6 mg/ 
day over a period of 2 weeks. One week later, he 
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came with severe drug induced parkinsonism for 
which trihexiphenidyl 4 mg/day was added. Within 
few days the pseudoparkinsonism subsided and 
trihexiphenidyl was stopped. Since then he was 
receiving only liquid risperidone and was 
maintained well with regular follow up once in 
every 2 months. 
After about 8 months, he was noticed to 
have dyskinetic movements of both hands and 
a to-and-fro nodding movement of head which 
was prominent when he was lying on the bed. 
These movements were absent during sieep. 
Due to dyskinesia, the risperidone dose was 
reduced to 2 mg/day and vitamin E (400 mg/ 
day) was added to the regimen. During the last 
4 months, he continues to have the same type 
of dyskinetic movements without progression but 
the psychotic symptoms are well controlled. 
Tardive dyskinesia is not a common side 
effect associated with risperidone treatment 
(Glazer,2000). Along with many risk factors, a 
history of early extrapyramidal symptoms (EPS) 
represents a possible risk factor for the later 
development of tardive dyskinesia (Owens, 
1994). As this patient has received risperidone 
as his main antipsychotic and as there was no 
dyskinetic movements in the past, the dyskinesia 
can be definitely considered as risperidone-
induced tardive dyskinesia. A pharmacological 
explanation could be that at a dose of 6 mg/day 
risperidone may lose the balanced 5HT2/D2 
blocking effect, resulting in more affinity for D2 
receptors, thereby producing comparable EPS 
with classical antipsychotics. As the same dose 
continues for long time, it can lead to 
supersensitivity of D2 receptors in the nigrostriatal 
system producing tardive dyskinesia. Jeste et al. 
(1996) have reported that Asian patients require tower 
doses of most psychotropic indications than do 
Caucasian patients which may explain why certain 
patients in India respond to risperidone at doses 
that are as low as 1 mg/day and react unfavourably 
to the therapeutic dose range of 6-8 mg/day. 
A single case we report is of heuristic value 
only. However, we believe that this case is 
unusually clear because of its antipsychotic drug 
naive status, complete prospective medication 
data, systematic tardive dyskinesia monitoring, 
8 months persistent dyskinesia, and dyskinesia 
free status preceeding risperidone treatment. We 
are currently enrolling patients who are beginning 
treatment with risperidone to further examine the 
issue of tardive dyskinesia. 
REFERENCES 
Addington,D.E., Toews.J.A. & 
Addington.J.M. (1995) Risperidone and tardive 
dyskinesia : a case report (letter). Journal of 
Clinical Psychiatry, 56, 484-485. 
Carroll.N.B., Boehm.K.E. & Strickland, 
R.T. (1999) Chorea and tardive dyskinesia in a 
patient taking risperidone (letter). Journal of 
Clinical Psychiatry, 60, 485-487. 
Chouinard.G. (1995) Effects of 
risperidone in tardive dyskinesia. Journal of 
Clinical Psychopharmacology, 15, suppl. 1,36-44. 
Glazer.W.M. (2000) Expected incidence 
of tardive dyskinesia associated with atypical 
antipsychotics. Journal of Clinical-Psychiatriy, 61, 
suppl. 4, 21-26. 
Gutierrez-Esteinou.R. & Grebb.J.A. 
(1997) Risperidone: an analysis of the first three 
years in general use. International Clinical 
Psychopharmacology, 12, suppl. 4, 3-10. 
Gwinn.K.A. & Caviners.J.N. (1997) 
Risperidone induced tardive dyskinesia and 
Parkinsonism. Movement Disorders, 12,119-121. 
Jeste,D.V., Lacro.J.P., Bailey.A., 
Rockwell,E., Harris,M.J. & Cafiguri.M.P. 
(1999) Lower incidence of tardive dyskinesia with 
risperidone compared with haloperidol in older 
patients. Journal of American Geriatrics Society, 
47, 716-719. 
Jeste,D.V., Lindamer.M.A., Evans,J. & 
79 P.N. SURESH KUMAR & CHITTARANJAN ANDRADE 
Lacro,J.P. (1996) Relationship of ethinicity and Saran.B.M. (1998) Risperidone induced 
gender to and pharmacology of neuroleptics, tardive dyskinesia (letter). Journal of Clinical 
Psychopharmacology Bulletin, 32, 243-251. Psychiatry, 59,29-30, 
Marder.S.R. & Meibach.R.C. (1994) Silberbauer (1998) Risperidone induced 
Risperidone in the treatment of schizophrenia, tardive dyskinesia! Pharmacopsychiatry, 31, 
American Journal of Psychiatry, 151, 825-835. 68-69. 
Owens.D.G.C. (1994) Extrapyramidal side Woener.M.G., Sheitman.B.B., 
effects and tolerability of risperidone : a review. Lieberman.J.A. & Kane.J.M. (1996) Tardive 
Journal of Clinical Psychiatry, 55, suppl. 5, dyskinesia induced by risperidone (letter)? 
29-35. American Journal of Psychiatry, 153,843. 
PN. SURESH KUMAR', MD,DPM.DNB(Psych),MNAMS. Senior Lecturer, Department of Psychiatry, Medical College, 
Calicut & CHITTARANJAN ANDRADE, MD. Additional Professor, Department of Psychopharmacology, NIMHANS, 
Bangalore ('M26 (A) 62. Malaparambha Housing Colony, Calicut -673 009). 
' Correspondence 
80 